Mesoblast

Clinical Trials Of Mesoblast’s Stem Cell Treatment For COVID-19 Set To Begin Soon
Clinical Trials Of Mesoblast’s Stem Cell Treatment For COVID-19 Set To Begin Soon
Forbes
Mesoblast
Australia
clinical gtrials
ARDS
COVID-19
stem cells
remestemcel-L
Flag link:
3 Biotech Stocks That Soared Last Week
3 Biotech Stocks That Soared Last Week
Motley Fool
Acadia Pharmaceuticals
Nuplazid
Mesoblast
Grunenthal
MPC-06-ID
Kodiak Sciences
age-related macular degeneration
Flag link:
Mesoblast poised to file cell therapy for GVHD in US
Mesoblast poised to file cell therapy for GVHD in US
Pharmaforum
Mesoblast
stem cells
graft vs host disease
FDA
remestemcel-L
Flag link:
Mesoblast defends stem cell therapy for heart failure after trial miss
Mesoblast defends stem cell therapy for heart failure after trial miss
Fierce Biotech
Mesoblast
stem cells
clinical trials
heart failure
Flag link:
Celgene buys into Mesoblast's stem cell pipeline in regenerative med pact
Celgene buys into Mesoblast's stem cell pipeline in regenerative med pact
Fierce Biotech
Celgene
Mesoblast
regenerative medicine
stem cells
Flag link:
Biotechnology companies hunting for the keys to immortality
Biotechnology companies hunting for the keys to immortality
FT.com
Mesoblast
aging
Calico
AlloCure
stem cells
Gilead Sciences
Flag link:
Mesoblast Is No Match For Pluristem's IP And Manufacturing
Mesoblast Is No Match For Pluristem's IP And Manufacturing
Seeking Alpha
Mesoblast
stem cells
Pluristem
Flag link:
Who Will Win The Stem Cell Race?
Who Will Win The Stem Cell Race?
Seeking Alpha
stem cells
Cytori
Athersys
Thermogenesis
Mesoblast
NeoStem
Flag link:
Teva gets approval from FDA for phase 3 heart failure trial
Teva gets approval from FDA for phase 3 heart failure trial
The Fly on the Wall
Teva
Mesoblast
FDA
congestive heart failure
Mesenchymal Precursor Cells
Flag link:
Osiris exits stem cell business, sells unit to Mesoblast in $100M deal
Osiris exits stem cell business, sells unit to Mesoblast in $100M deal
Fierce Biotech
Mesoblast
Osiris
stem cells
M&A
Flag link:
Pluristem Standardizes Stem Cell Therapy, Opening Door To The Future Of Medicine
Pluristem Standardizes Stem Cell Therapy, Opening Door To The Future Of Medicine
Seeking Alpha
Pluristem
stem cells
Mesoblast
Osiris
Thermo Fisher
Flag link:
The Next Big Growth Sector In Health Care: Stem Cell Therapy
The Next Big Growth Sector In Health Care: Stem Cell Therapy
Seeking Alpha
stem cells
Advanced Cell Technology
Advanced Micro Devices
Arthersys
Neuralstem
Mesoblast
Pfizer
Teva Pharmaceuticals
Flag link:
Biotech 2012 Kickoff Party: Investor Preview
Biotech 2012 Kickoff Party: Investor Preview
TheStreet.com
Celgene
Vivus
Dendreon
Gilead
Incyte
YM BioSciences
ONYX Pharmaceuticals
Seattle Genetics
Vertex
Amarin
Biomarin
Biogen Idec
Regeneron
Merck KGaA
Human Genome Sciences
Clovis Oncology
Roche
Ariad
Immunogen
Medivation
Geron
InterMune
Indenix
Amag Pharmaceuticals
Mesoblast
Arena
MannKind
Keryx
Spectrum Pharmaceuticals
Flag link:
FACTBOX-Stem cell advances focus on heart, inflammation
FACTBOX-Stem cell advances focus on heart, inflammation
Reuters
stem cells
inflammation
Aastrom
Arthersys
Baxter
Celgene
Cytori
Mesoblast
Fibrocell Science
StemCells
Pluristem
Osiris
Pharmicell
NeoStem
Neuralstem
Gamida Cell
Flag link:
Athersys Shares Poised To Move Higher
Athersys Shares Poised To Move Higher
Seeking Alpha
Athersys
Pfizer
Mesoblast
Cephalon
Geron
Flag link:
Teva Pharma Is ‘Ideal Partner,’ Mesoblast CEO Itescu Says
Teva Pharma Is ‘Ideal Partner,’ Mesoblast CEO Itescu Says
Bloomberg
Teva Pharmaceuticals
Mesoblast
Flag link:
Time to Buy Into Stem Cells?
Time to Buy Into Stem Cells?
Motley Fool
stem cells
Geron
Neuralstem
StemCells
Pfizer
GSK
Cephalon
Mesoblast
Merck
Alnylam
Flag link:
Cephalon Stem Cell Deal Catches Analysts Off-Guard
Cephalon Stem Cell Deal Catches Analysts Off-Guard
Seeking Alpha
stem cells
Cephalon
Mesoblast
Flag link:
Cephalon Buys Mesoblast Stake, Drug Rights in Potential $2 Billion Deal
Cephalon Buys Mesoblast Stake, Drug Rights in Potential $2 Billion Deal
Bloomberg
Cephalon
Mesoblast
stem cells
Flag link:
Stem Cell Developer Mesoblast Seeks Bone Marrow Therapy by 2012
Stem Cell Developer Mesoblast Seeks Bone Marrow Therapy by 2012
Bloomberg
stem cells
Mesoblast
Angioblast
Flag link: